Ariel Investments, an investment management company, released its “Ariel Focus Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The Fund returned 2.14% in the second quarter of 2026, underperforming the Russell 1000 Value and S&P 500, which gained 13.87% and 15.20%, respectively. The fund benefited from gains in several holdings, while weaker performances in energy, consumer healthcare, and gold mining weighed on results. U.S. stocks rallied sharply as easing geopolitical tensions, lower oil prices, and resilient earnings boosted investor confidence, with technology, semiconductors, and AI-related stocks leading the recovery. Looking ahead, Ariel Investments expects modest and uneven global growth, continued geopolitical risks, and pressure from inflation and borrowing costs, but remains focused on long-term value creation through bottom-up research and investments in durable businesses with strong balance sheets and competitive advantages. In addition, please check the Fund’s top five holdings to know its best picks in 2026.
In its second-quarter 2026 investor letter, Ariel Focus Fund highlighted stocks like DENTSPLY SIRONA Inc. (NASDAQ:XRAY). DENTSPLY SIRONA Inc. (NASDAQ:XRAY) develops and manufactures dental equipment, technologies, and consumable products for dental professionals worldwide. The one-month return of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) was 8.52% while its shares traded between $9.41 and $14.86 over the last 52 weeks. On July 31, 2026, DENTSPLY SIRONA Inc. (NASDAQ:XRAY) stock closed at approximately $13.74 per share, with a market capitalization of about $2.678 billion.
Ariel Focus Fund stated the following regarding DENTSPLY SIRONA Inc. (NASDAQ:XRAY) in its Q2 2026 investor letter:
Also during the quarter, we added Dentsply Sirona (NASDAQ:XRAY), a leading global dental manufacturing company, to the portfolio. Since acquiring Sirona Dental in 2016, the company has faced challenges, particularly in its core capital equipment business, which has come under pressure from lower-cost technology alternatives and higher interest rate financing. Despite these headwinds, we like the attractive dynamics of the dental market including its steady growth and lower reimbursement risk compared to other healthcare segments. Management is executing a strategic reset focused on debt paydown, innovative product development and portfolio expansion, operational efficiencies, emerging market growth and bolt-on acquisitions. With these initiatives underway, we believe XRAY should be able to capitalize on secular growth trends, improve margins and drive long-term shareholder value.
George Rudy/Shutterstock.com
DENTSPLY SIRONA Inc. (NASDAQ:XRAY) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. As per our database, 41 hedge fund portfolios held DENTSPLY SIRONA Inc. (NASDAQ:XRAY) at the end of the first quarter, which was 38 in the previous quarter. While we acknowledge the risk and potential of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than DENTSPLY SIRONA Inc. (NASDAQ:XRAY) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered DENTSPLY SIRONA Inc. (NASDAQ:XRAY) and shared the list of stocks that were discussed by Jim Cramer. In addition, please check out our hedge fund investor letters Q1 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. This article is originally published at Insider Monkey.
